Survival in cancer of unknown primary site: Population-based analysis by site and histology

Annals of Oncology

Volumn 23, Issue 7, 2012, Pages 1854-1863

  Hemminki, K ^a,b   Bevier, M ^a   Hemminki, A ^c   Sundquist, J ^b,d  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b LUND UNIVERSITY   (Sweden)

^c UNIVERSITY OF HELSINKI   (Finland)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Histology; Metastasis; Prognosis; Survival

Indexed keywords

ABDOMINAL CANCER; ADENOCARCINOMA; ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; CANCER LOCALIZATION; CANCER OF UNKNOWN PRIMARY SITE; CANCER PROGNOSIS; CANCER REGISTRY; CANCER SURVIVAL; CHILD; CLINICAL DECISION MAKING; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HEAD AND NECK CANCER; HISTOLOGY; HUMAN; INFANT; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PELVIS LYMPH NODE; PRIORITY JOURNAL; RELIABILITY; SCHOOL CHILD; SURVIVAL RATE; SURVIVAL TIME;

EID: 84864323806     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr536     Document Type: Article

References (28)

1. van de Wouw AJ, Janssen-Heijnen ML, Coebergh JW, Hillen HF. Epidemiology of unknown primary tumours; incidence and population-based survival of 1285 patients in Southeast Netherlands, 1984-1992. Eur J Cancer 2002; 38: 409-413.
2. Randen M, Rutqvist LE, Johansson H. Cancer patients without a known primary: incidence and survival trends in Sweden 1960-2007. Acta Oncol 2009; 48: 915-920.
3. Pavlidis N, Fizazi K. Carcinoma of unknown primary (CUP). Crit Rev Oncol Hematol 2009; 69: 271-278.
4. Kramer A, Hubner G, Schneeweiss A et al. Carcinoma of unknown primary-an orphan disease?. Breast Care (Basel) 2008; 3: 164-170.
5. Freudenberg LS, Rosenbaum-Krumme SJ, Bockisch A et al. Cancer of unknown primary. Recent results. Cancer Res 2008; 170: 193-202.
6. Hemminki K, Ji J, Sundquist J, Shu X. Familial risks in cancer of unknown primary: tracking the primary sites. J Clin Oncol 2011; 29: 435-440.
7. Hainsworth JD, Fizazi K. Treatment for patients with unknown primary cancer and favorable prognostic factors. Semin Oncol 2009; 36: 44-51.
8. Monzon FA, Koen TJ. Diagnosis of metastatic neoplasms: molecular approaches for identification of tissue of origin. Arch Pathol Lab Med 2010; 134: 216-224.
9. Hemminki K, Liu H, Hemminki A, Sundquist J. Power and limits of modern cancer diagnostics: cancer of unknown primary. Ann Oncol 2012; 23: 760-764.
10. Fizazi K, Greco FA, Pavlidis N, Pentheroudakis G. Cancer of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011; 22: vi64-vi68.
11. Abbruzzese JL, Abbruzzese MC, Lenzi R et al. Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin. J Clin Oncol 1995; 13: 2094-2103.
12. Abbruzzese JL, Abbruzzese MC, Hess KR et al. Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. J Clin Oncol 1994; 12: 1272-1280.
13. Hess KR, Abbruzzese MC, Lenzi R et al. Classification and regression tree analysis of 1000 consecutive patients with unknown primary carcinoma. Clin Cancer Res 1999; 5: 3403-3410.
14. Altman E, Cadman E. An analysis of 1539 patients with cancer of unknown primary site. Cancer 1986; 57: 120-124.
15. van der Gaast A, Verweij J, Planting AS et al. Simple prognostic model to predict survival in patients with undifferentiated carcinoma of unknown primary site. J Clin Oncol 1995; 13: 1720-1725.
16. Lenzi R, Hess KR, Abbruzzese MC et al. Poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown origin: favorable subsets of patients with unknown-primary carcinoma?. J Clin Oncol 1997; 15: 2056-2066.
17. Culine S. Prognostic factors in unknown primary cancer. Semin Oncol 2009; 36: 60-64.
18. Pavlidis N, Briasoulis E, Hainsworth J, Greco FA. Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer 2003; 39: 1990-2005.
19. Pavlidis N, Briasoulis E, Pentheroudakis G. Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21(Suppl 5): v228-v231.
20. Sleeman JP, Nazarenko I, Thiele W. Do all roads lead to Rome? Routes to metastasis development. Int J Cancer 2011; 128: 2511-2526.
21. Greco FA, Pavlidis N. Treatment for patients with unknown primary carcinoma and unfavorable prognostic factors. Semin Oncol 2009; 36: 65-74.
22. Shu X, Liu H, Ji J et al. Subsequent cancers in patients diagnosed with cancer of unknown primary (CUP): etiological insights? Ann Oncol 2012; 23: 269-275.
23. Centre for Epidemiology. Cancer Incidence in Sweden 2005 Stockholm, Sweden: The National Board of Health and Welfare 2007.
24. Chen LL, Blumm N, Christakis NA et al. Cancer metastasis networks and the prediction of progression patterns. Br J Cancer 2009; 101: 749-758.
25. Curiel TJ, Wei S, Dong H et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med 2003; 9: 562-567.
26. Lazaridis G, Pentheroudakis G, Fountzilas G, Pavlidis N. Liver metastases from cancer of unknown primary (CUPL): a retrospective analysis of presentation, management and prognosis in 49 patients and systematic review of the literature. Cancer Treat Rev 2008; 34: 693-700.
27. Bartelt S, Lutterbach J. Brain metastases in patients with cancer of unknown primary. J Neurooncol 2003; 64: 249-253.
28. Kamposioras K, Pentheroudakis G, Pectasides D, Pavlidis N. Malignant melanoma of unknown primary site. To make the long story short. A systematic review of the literature. Crit Rev Oncol Hematol 2010; 78: 112-126.